Clearside Biomedical Inc Market Cap ($2.15 Million)
Market Cap & Net Worth: Clearside Biomedical Inc (CLSD)
Clearside Biomedical Inc market cap. Clearside Biomedical Inc (NASDAQ:CLSD) has a market capitalization of $2.15 Million ($2.15 Million) as of October 30, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #29989 globally and #6124 in its home market, demonstrating a -85.66% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Clearside Biomedical Inc's stock price $0.41 by its total outstanding shares 5233981 (5.23 Million).
Clearside Biomedical Inc Market Cap History (2016–2025)
Clearside Biomedical Inc market cap history from 2016 to 2025. Data shows change from $46.79 Million to $2.15 Million (-26.10% CAGR). Check Clearside Biomedical Inc stock quote for real-time trading data and today's change.
Index Memberships
Clearside Biomedical Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.00% | #870 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #2778 of 3165 |
Weight: Clearside Biomedical Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Clearside Biomedical Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Clearside Biomedical Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see CLSD operating cash flow for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2.99x
Clearside Biomedical Inc's market cap is 2.99 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $46.79 Million | $520.00K | -$25.88 Million | 89.98x | N/A |
| 2017 | $36.64 Million | $345.00K | -$58.98 Million | 106.20x | N/A |
| 2018 | $5.60 Million | $30.00K | -$82.82 Million | 186.68x | N/A |
| 2019 | $15.18 Million | $2.17 Million | -$30.56 Million | 6.99x | N/A |
| 2020 | $14.34 Million | $7.89 Million | -$18.03 Million | 1.82x | N/A |
| 2021 | $14.39 Million | $29.57 Million | $376.00K | 0.49x | 38.28x |
| 2022 | $5.86 Million | $1.33 Million | -$32.95 Million | 4.42x | N/A |
| 2023 | $6.12 Million | $8.23 Million | -$32.48 Million | 0.74x | N/A |
| 2024 | $4.97 Million | $1.66 Million | -$34.35 Million | 2.99x | N/A |
Competitor Companies of CLSD by Market Capitalization
Companies near Clearside Biomedical Inc in the global market cap rankings as of October 30, 2026. See Clearside Biomedical Inc balance sheet quality to understand what proportion of total assets are financed by equity.
Key companies related to Clearside Biomedical Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #183 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #374 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #422 globally with a market cap of $67.80 Billion USD ( AU$95.82 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #498 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #183 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $540.00 |
| #374 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $818.77 |
| #422 | CSL Ltd | AU:CSL | $67.80 Billion | AU$197.50 |
| #498 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $222.76 |
Market Capitalization of Clearside Biomedical Inc (2016–2025)
Market capitalization of Clearside Biomedical Inc from 2016 to today. Between 2016 and today, Clearside Biomedical Inc's market cap moved from $46.79 Million to $ 2.15 Million, with a yearly change of -26.10%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.15 Million | -56.84% |
| 2024 | $4.97 Million | -18.80% |
| 2023 | $6.12 Million | +4.46% |
| 2022 | $5.86 Million | -59.27% |
| 2021 | $14.39 Million | +0.36% |
| 2020 | $14.34 Million | -5.52% |
| 2019 | $15.18 Million | +171.03% |
| 2018 | $5.60 Million | -84.71% |
| 2017 | $36.64 Million | -21.70% |
| 2016 | $46.79 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Clearside Biomedical Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.15 Million USD |
| MoneyControl | $2.15 Million USD |
| MarketWatch | $2.15 Million USD |
| marketcap.company | $2.15 Million USD |
| Reuters | $2.15 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Clearside Biomedical Inc
Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, whic… Read more